Alto Neuroscience Stock

altoneuroscience.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $253.17MM

Alto Neurosciences is a biopharma company that uses biomarkers of the brain to understand prospective drug therapies for psychiatric care of patients. Alto Neurosciences specializes in precision medicine, and has established a pipeline of treatments for various mental health conditions such as post-traumatic stress disorders (PTSD) and depression.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Alto Neuroscience before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Alto Neuroscience Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Alto Neuroscience Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
11/21/2023 Series C $50.31MM $xx.xx $235.65MM Alexandria Venture Investments, Alkeon Capital, Alpha Wave Ventures, Eli Lilly & Company, Franklin Templeton, Invivium Capital, Lightswitch Capital, Point72, Whatif Ventures, Windham Venture Partners
Price per Share
$xx.xx
Shares Outstanding
10,674,967
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Alkeon Capital, Alpha Wave Ventures, Eli Lilly & Company, Franklin Templeton, Invivium Capital, Lightswitch Capital, Point72, Whatif Ventures, Windham Venture Partners
01/30/2023 Series B $59.26MM $xx.xx $218.32MM Alkeon Capital, Alpha Wave Ventures, Aperion Group, Gaingels, Korify Capital, Lightswitch Capital, Novartis Pharma Ag, Sobrato Capital, Valor Equity Partners, Vine Ventures, What If Ventures, Windham Venture Partners
Price per Share
$xx.xx
Shares Outstanding
9,876,955
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alkeon Capital, Alpha Wave Ventures, Aperion Group, Gaingels, Korify Capital, Lightswitch Capital, Novartis Pharma Ag, Sobrato Capital, Valor Equity Partners, Vine Ventures, What If Ventures, Windham Venture Partners
10/14/2021 Series A $34.08MM $xx.xx $128.77MM Able Partners, Aperion Investment Group, Tim Kendall, What If Ventures, Windham Partners
Price per Share
$xx.xx
Shares Outstanding
7,250,992
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Able Partners, Aperion Investment Group, Tim Kendall, What If Ventures, Windham Partners
09/30/2019 Series Seed $7.72MM $xx.xx $30.89MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
3,708,682
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Alto Neuroscience Investors Also Invested in These Private Companies

Vine Ventures
Windham Venture Partners
Sobrato Capital
Korify Capitals
Bioverge Ventures
Lightswitch Capital
Catena Capital

Leadership & Board

Leadership

Amit Etkin Ph.D
Co-Founder & Chief Executive Officer
Nick Smith
Chief Financial Officer & Chief Business Officer
Dan Segal
Co-Founder, Chief Strategy Officer & Chief Operating Officer
Mikael Eliasson MD
Chief Operating Officer
Erin McQuade JD
Chief Administrative Officer & General Counsel
Jessica Powell
Chief Development Officer
Wei Wu Ph.D
Co-Founder & Chief Data Science Officer
Adam Savitz Ph.D
Chief Medical Officer

Board

Aaron Weaver
Apeiron Investment Group
Chris Dimitropoulos
Alpha Wave Global
Christopher Cox JD
Lightswitch Capital
Michael Liang Ph.D
InVivium Capital

Alto Neuroscience stock FAQs

plusminus

Can you buy Alto Neuroscience stock?

You can no longer buy Alto Neuroscience stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Alto Neuroscience stock?

You can no longer buy Alto Neuroscience stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Alto Neuroscience stock?

You can no longer sell stock of Alto Neuroscience on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Alto Neuroscience stock?

You can no longer sell stock of Alto Neuroscience on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Alto Neuroscience a public company?

Alto Neuroscience is now a public company traded on NASDAQ with ticker ANRO.
plusminus

What is Alto Neuroscience’s stock price?

The stock price of Alto Neuroscience is not currently available.
plusminus

What is Alto Neuroscience’s stock ticker symbol?

The ticker symbol of Alto Neuroscience is ANRO.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Alto Neuroscience News and Media Highlights

Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing

Alto Neuroscience, Inc. today announced an oversubscribed $45 million Series C financing. The round was led by InVivium Capital, with participation from additional new investors Franklin Templeton, Point72, Eli Lilly and Company, and Alexandria Venture Investments. Existing investors Alpha Wave Ventures, Lightswitch Capital, partners of Alkeon Capital, WhatIf Ventures, and Windham Venture Partners also participated in the financing.

Alto Neuroscience Announces $35 Million Series B Financing

Alto Neuroscience today announced the closing of a $35 million Series B financing led by Lightswitch Capital and partners of Alkeon Capital, with participation from other new investors including Sobrato Capital, Novartis Pharma AG, Valor Equity Partners, Korify Capital, Vine Ventures, and Gaingels.
Browse Insights
Updated on: Dec 3, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.